Digest Network Come funziona
Network
/
Società
Re
Non verificato

Retension Pharmaceuticals

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

2 comunicati stampa

Guarda tutti i comunicati
27/05/2026
Mercato del lavoro
Medicina alternativa
Salute
Sanità
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Retension Pharmaceuticals Appoints Alison Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer
Fonte
Retension Pharmaceuticals
Emittente
Business Wire
1.00
0
06/08/2025
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resistant Hypertension and Issuance of a New U.S. Patent Covering its Lead Candidate, RTN-001
Fonte
Retension Pharmaceuticals
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0